Core Viewpoint - The stock of Boan Biotechnology (06955) fell over 8% following the release of its interim results, indicating market concerns regarding its profitability despite revenue growth [1] Financial Performance - For the first half of the year, Boan Biotechnology reported revenue of RMB 393 million, an increase of 8.4% year-on-year [1] - Gross profit remained stable at RMB 283 million, showing no significant change compared to the previous year [1] - The profit attributable to the parent company was RMB 20.514 million, a decrease of 66.7% year-on-year [1] Product Sales - The increase in revenue was primarily driven by the sales of products (Boan's You Nuo, Boan's You Bei, and Bo Luo Jia), which grew by 15.9% to RMB 385.3 million for the six months ending June 30, 2024 [1] Regulatory Approval - On August 9, Boan Biotechnology announced that its self-developed product, Boan You Ping (Dulaglutide injection), received approval from the National Medical Products Administration for market launch [1] - This product is the world's first and currently the only approved biosimilar to Trulicity, with no other domestic Dulaglutide injections having entered the market approval application stage [1] - The commercialization of Boan You Ping in mainland China will be conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd. [1]

博安生物(06955)绩后跌超8%，截至发稿，跌7.06%，报14.61港元，成交额9830.77万港元。 消息面上，博安生物发布中期业绩，上半年收入人民币3.93亿元，同比增加8.4%；毛利为人民币2.83亿 元，同比基本持平；母公司拥有人应占溢利为人民币2051.4万元，同比减少66.7%。期内收入增加主要 是由于产品(博优诺、博优倍及博洛加)销售较截至2024年6月30日止六个月持续增长15.9%至人民币3.853 亿元。 值得注意的是，8月9日，博安生物宣布，其自主研发的博优平(度拉糖肽注射液)已获得国家药品监督管 理局的上市批准，用于成人2型糖尿病患者的血糖控制。该产品是全球首个且当前唯一获批上市的度易 达(英文商品名：Trulicity)的生物类似药，国内尚无其他国产度拉糖肽注射液进入上市许可申请阶段。 博优平在中国大陆的商业化由博安生物与上药控股有限公司(上药控股)合作开展。 ...

Core Viewpoint - The company reported a revenue of RMB 393.4 million for the six months ending June 30, 2025, representing an 8.4% year-on-year increase, while the net profit attributable to the parent company decreased by 66.7% to RMB 20.5 million [1][2]. Financial Performance - Revenue for the period was RMB 393.4 million, up from RMB 362.9 million in the same period last year [2]. - Gross profit remained relatively stable at RMB 282.6 million, compared to RMB 282.6 million in the previous year [2]. - The sales cost increased significantly to RMB 110.8 million from RMB 80.3 million, indicating a rise in operational expenses [2]. - Other income and gains decreased sharply to RMB 2.6 million from RMB 36.1 million [2]. - Research and development costs were reduced to RMB 58.6 million from RMB 85.8 million, reflecting a strategic focus on cost management [2]. - Administrative expenses slightly decreased to RMB 23.2 million from RMB 24.3 million [2]. - Selling and distribution expenses increased to RMB 159.8 million from RMB 134.2 million, indicating higher marketing efforts [2]. - Financial costs rose to RMB 19.5 million from RMB 12.6 million, impacting overall profitability [2]. Profitability Metrics - The profit before tax was RMB 20.5 million, down from RMB 61.7 million in the previous year [2]. - Basic earnings per share decreased to RMB 0.04 from RMB 0.12, reflecting the decline in net profit [2]. - Total comprehensive income for the period was RMB 20.4 million, significantly lower than RMB 61.6 million from the previous year [2].

Core Viewpoint - The company reported a revenue of 393 million RMB for the six months ending June 30, 2025, reflecting an 8.39% year-on-year increase, while the net profit attributable to shareholders decreased by 66.74% to 20.514 million RMB [1] Revenue Performance - The revenue increase was primarily driven by the sales growth of products (Bo Younuo, Bo Youbei, and Bo Luojia), which rose by 15.9% to 385 million RMB compared to the six months ending June 30, 2024 [1]